Losing payment access is the most common way a peptide business stops operating, and it rarely happens at application. It happens months later, when an underwriting review compares the live site against the description the merchant provided — and the two do not match.
Nothing here is legal or underwriting advice, and no processor's decision can be predicted from the outside. But the underwriting logic is not mysterious, and most of what it measures is within the merchant's control.
What a risk classification is actually measuring
'High risk' in card-network terms is not a moral judgement about a category. It is a prediction about the probability that the acquiring bank ends up financially exposed. Four inputs drive it.
| Input | What the underwriter is estimating |
|---|---|
| Chargeback probability | How often customers will dispute, and whether the merchant can rebut with delivery evidence |
| Regulatory exposure | Whether the merchant's own marketing could attract an enforcement action that stops the business |
| Fulfilment reliability | Whether goods ship as described, on the stated timeline |
| Longevity | Whether the business will still exist to cover future disputes and refunds |
The mismatch problem
The most consequential factor is consistency. An account approved on the basis of a description that the live site contradicts is not a durable account — it is an account awaiting a review.
This is where the same claim discipline that governs regulatory exposure does double duty. A site that describes research materials in one place and implies human use in another has created a discrepancy that underwriting will eventually find, regardless of which statement the merchant considers authoritative.
What is within a merchant's control
- Accuracy at application. Describing the business precisely is the only foundation a durable account can sit on.
- Claim consistency across every public surface, reviewed on a schedule rather than once at launch.
- Descriptor clarity. A billing descriptor customers recognise measurably reduces 'I don't recognise this charge' disputes.
- Delivery evidence. Tracking, delivery confirmation and dated records are what a dispute is actually won with.
- Refund responsiveness. A refund is cheaper than a chargeback in both cost and ratio impact.
- Redundancy. A second processing relationship established before it is needed, not during a termination.
- Reserve planning. Treat a rolling reserve as the baseline assumption in cash-flow modelling.
What is not within a merchant's control
Category-level policy changes at the card networks or the acquiring bank can affect compliant merchants with no warning and no fault. Portfolio decisions can close accounts that were performing well. Underwriting standards vary between providers and change over time.
The rational response to that is not to try to predict it. It is to keep the controllable inputs clean and to maintain redundancy, so that a policy change is a disruption rather than an ending.
Verify claims made by processors too
The high-risk processing market includes intermediaries whose own marketing deserves the same scrutiny a merchant would apply to a supplier. Establish who the actual acquiring bank is, what the reserve terms are in writing, what the termination provisions say, and what happens to held funds — before signing.
Therapept does not maintain a processor directory. Processor policies for this category change frequently enough that a published list would be misleading within months, and a stale recommendation in this area is worse than none.
Sources
- FTC — Health Products Compliance Guidance
- FDA — Warning Letters and enforcement actions
- CFPB — Consumer complaint database (payments and money transfer)Public record of consumer-side payment disputes.
This article is informational. It is not medical, legal or financial advice. Editorial policy · Report a correction